Jisun Lee
NPI 1982187027 · Foot & Ankle Surgery Podiatrist · Palo Alto, CA
Enrolled with Medicare as Practitioner - Podiatry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1982187027
- Entity type
- Individual
- Primary specialty
- Foot & Ankle Surgery PodiatristPodiatric Medicine & Surgery Service Providers
- Sex
- Female
- Sole proprietor
- No
- License
- 6846 (CA)
Specialties & taxonomies
Podiatric Medicine & Surgery Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
7 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
2,824 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 672 | $110 |
| Removal of Noncancer Thickened Skin Growth, 2-4 Growths11056 | 353 | $109 |
| Test Or Measurement for Functional Capacity, Each 15 Minutes97750 | 287 | $36 |
| Removal of Skin and Tissue, 20.0 Sq Cm Or Less11042 | 203 | $67 |
| Detection Test By Nucleic Acid for Organism, Amplified Probe Technique87798 | 195 | $34 |
| X-Ray of Foot, Minimum of 3 Views73630 | 162 | $46 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 7 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Amoxicillin/Potassium Clavbrand: Amoxicillin-Clavulanate Potass | 36 | 28 |
| Gabapentin | 33 | — |
| Celecoxib | 18 | 12 |
| Methylprednisolone | 15 | 14 |
| Meloxicam | 12 | — |
| Sulfamethoxazole/Trimethoprimbrand: Sulfamethoxazole-Trimethoprim | 12 | 12 |
| Terbinafine Hcl | 11 | — |
These counts cover prescriptions paid through Medicare Part D in 2024 — they include cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means , never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$423 across 13 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2018-09-14
- Last updated
- 2018-09-14
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.